TAKAYASU ARTERITIS MASQUERADING AS IDIOPATHIC DILATED CARDIOMYOPATHY: DEMONSTRATING DIAGNOSTIC PITFALLS AND SUCCESSFUL ENDOVASCULAR MANAGEMENT

Main Article Content

Manish Shaw
Surya Pratap Singh
Amarinder Singh Malhi

Keywords

takayasu arteritis, dilated cardiomyopathy, heart failure

Abstract

Takayasu arteritis (TA) is a chronic granulomatous vasculitis affecting large vessels, with cardiovascular complications occurring in approximately 40% of patients¹. Dilated cardiomyopathy (DCM) represents an uncommon but serious manifestation, occurring in 6% of TA cases². The nonspecific presentation often leads to misdiagnosis as idiopathic DCM, particularly when blood pressure appears normal due to cardiac dysfunction³. Early recognition is crucial as endovascular intervention can significantly improve cardiac function⁴. This study examines cases initially misdiagnosed as idiopathic DCM, subsequently identified as TA, highlighting diagnostic challenges and demonstrating successful endovascular management strategies in this vulnerable population.


Methods : We conducted a retrospective analysis of our institutional databases (January 2018-December 2023) identifying patients initially diagnosed with idiopathic DCM who were subsequently confirmed to have TA. Data collection included demographics, clinical presentation, laboratory markers (ESR, CRP), multimodality imaging (echocardiography, CT, MRI, angiography), intervention details, and follow-up outcomes. Primary endpoints included correct diagnosis establishment and procedural success. Secondary endpoints assessed left ventricular ejection fraction (LVEF) improvement and symptom resolution at follow-up.


Results: Eight patients (6 females, 2 males; mean age 15 years, range 11-20) were identified. All presented with NYHA class II-III symptoms and LVEF 15-35%. Diagnostic workup revealed elevated inflammatory markers in all cases. Vascular involvement included descending thoracic aortic stenosis (n=5), bilateral renal artery stenosis (n=2), and diffuse aortitis with myocarditis (n=1). All patients underwent endovascular intervention with technical success achieved in all procedures. Mean LVEF improved from 25% to 45% at 6-month follow-up. NYHA class improved to I-II in all patients. One patient required repeat intervention for restenosis, ultimately requiring surgical planning. No procedure-related complications occurred.


Conclusions: TA should be considered in young patients presenting with DCM, particularly in endemic regions. Key diagnostic clues include elevated inflammatory markers, abnormal pulse examination, and increased carotid intima-media thickness. Multimodality imaging is essential for diagnosis. Endovascular intervention provides effective management with significant cardiac function improvement. A multidisciplinary approach involving cardiology, rheumatology, and interventional radiology optimizes outcomes. Systematic screening protocols could prevent diagnostic delays and improve long-term prognosis in this population.

Abstract 0 | Pdf Downloads 0

References

1. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11):919-929.Matsubara O, Yoshimura N, Tamura A, et al. Pathological features of the pulmonary artery in Takayasu arteritis. Heart Vessels Suppl. 1992;7:52-59.
2. Ismail Y. Takayasu arteritis with cardiac involvement: systematic review of the literature. Eur Heart J. 2019;40(Supplement_1):ehz745.0391.
3. Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis. Circulation. 2012;125(6):813-819.
4. Takayasu M. Case with unusual changes of the central vessels in the retina. Acta Soc Ophthalmol Jpn. 1908;12:554-555.
5. Mwipatayi BP, Jeffery PC, Beningfield SJ, et al. Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg. 2005;75(3):110-117.
6. Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of Takayasu arteritis in India. Int J Cardiol. 1996;54:S111-S116.
7. Brunner J, Feldman BM, Tyrrell PN, et al. Takayasu arteritis in children and adolescents. Rheumatology. 2010;49(10):1806-1814.
8. Numano F, Okawara M, Inomata H, Kobayashi Y. Takayasu's arteritis. Lancet. 2000;356(9234):1023-1025.
9. Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, et al. Takayasu's arteritis: clinical study of 107 cases. Am Heart J. 1977;93(1):94-103.
10. Talwar KK, Chopra P, Narula J, et al. Myocardial involvement and its response to immunosuppressive therapy in nonspecific aortoarteritis (Takayasu's disease). Int J Cardiol. 1988;21(3):323-334.
11. Soto ME, Espinola N, Flores-Suarez LF, Reyes PA. Takayasu arteritis: clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S9-S15.
12. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine. 2009;88(4):221-226.
13. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-1876.
14. Bicakcigil M, Aksu K, Kamali S, et al. Takayasu's arteritis in Turkey - clinical and angiographic features of 248 patients. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S59-S64.
15. Ishikawa K, Maetani S. Long-term outcome for 120 Japanese patients with Takayasu's disease. Clinical and statistical analyses of related prognostic factors. Circulation. 1994;90(4):1855-1860.
16. Sharma BK, Jain S, Suri S, Numano F. Diagnostic criteria for Takayasu arteritis. Int J Cardiol. 1996;54:S141-S147.
17. Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc. 2013;88(8):822-830.
18. Fields CE, Bower TC, Cooper LT, et al. Takayasu's arteritis: operative results and influence of disease activity. J Vasc Surg. 2006;43(1):64-71.
19. Kim YW, Kim DI, Park YJ, et al. Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg. 2012;55(3):693-700.
20. Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30.
21. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129-1134.
22. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little, Brown & Co; 1994:253-256.Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults. J Am Soc Echocardiogr. 2015;28(1):1-39.
23. Chung JW, Kim HC, Choi YH, et al. Patterns of aortic involvement in Takayasu arteritis and its clinical implications: evaluation with spiral computed tomography angiography. J Vasc Surg. 2007;45(5):906-914.
24. Nastri MV, Baptista LP, Baroni RH, et al. Gadolinium-enhanced three-dimensional MR angiography of Takayasu arteritis. Radiographics. 2004;24(3):773-786.
25. Sharma S, Gupta H, Saxena A, et al. Results of renal angioplasty in nonspecific aortoarteritis (Takayasu disease). J Vasc Interv Radiol. 1998;9(3):429-435.
26. Tyagi S, Kaul UA, Nair M, et al. Balloon angioplasty of the aorta in Takayasu's arteritis: initial and long-term results. Am Heart J. 1992;124(4):876-882.
27. Min PK, Park S, Jung JH, et al. Endovascular therapy combined with immunosuppressive treatment for occlusive arterial disease in patients with Takayasu's arteritis. J Endovasc Ther. 2005;12(1):28-34.
28. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.
29. Dong H, Jiang X, Peng M, et al. Percutaneous transluminal angioplasty for symptomatic pulmonary stenosis in Takayasu arteritis. J Rheumatol. 2014;41(7):1483-1486.
30. Sharma S, Thatai D, Saxena A, et al. Renovascular hypertension resulting from nonspecific aortoarteritis in children: midterm results of percutaneous transluminal renal angioplasty and predictors of restenosis. AJR Am J Roentgenol. 1996;166(1):157-162.
31. Keenan NG, Mason JC, Maceira A, et al. Integrated cardiac and vascular assessment in Takayasu arteritis by cardiovascular magnetic resonance. Arthritis Rheum. 2009;60(11):3501-3509.
32. Subramanyan R, Joy J, Balakrishnan KG. Natural history of aortoarteritis (Takayasu's disease). Circulation. 1989;80(3):429-437.
33. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37(4):578-582.
34. Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: A study of 104 Italian patients. Arthritis Rheum. 2005;53(1):100-107.
35. Raninen RO, Kupari MM, Pamilo MS, et al. Arterial wall thickness measurements by B-mode ultrasonography in patients with Takayasu's arteritis. Ann Rheum Dis. 1996;55(7):461-465.
36. Tso E, Flamm SD, White RD, et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum. 2002;46(6):1634-1642.
37. Yamada I, Nakagawa T, Himeno Y, et al. Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. Radiology. 1998;209(1):103-109.
38. Park MC, Lee SW, Park YB, et al. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology. 2006;45(5):600-605.
39. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol. 2004;31(1):102-106.
40. Jeong HS, Jung JH, Song GG, et al. Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: A meta-analysis. Medicine. 2017;96(29):e7558.
41. Kalangos A, Christenson JT, Cikirikcioglu M, et al. Long-term outcome after surgical intervention and interventional procedures for the management of Takayasu's arteritis in children. J Thorac Cardiovasc Surg. 2006;132(3):656-664.
42. Park JH, Chung JW, Im JG, et al. Takayasu arteritis: evaluation of mural changes in the aorta and pulmonary artery with CT angiography. Radiology. 1995;196(1):89-93.
43. Ham SW, Kumar SR, Wang BR, et al. Late outcomes of endovascular and open revascularization for nonatherosclerotic renal artery disease. Arch Surg. 2010;145(9):832-839.
44. Sharma BK, Jain S, Sagar S. Systemic manifestations of Takayasu arteritis: the expanding spectrum. Int J Cardiol. 1996;54:S149-S154.
45. Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am. 1995;21(4):1041-1058.
46. Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu's disease). Circulation. 1978;57(1):27-35.
47. Seth S, Goyal NK, Jagia P, et al. Carotid intima-medial thickness as a marker of disease activity in Takayasu's arteritis. Int J Cardiol. 2006;108(3):385-390.
48. Direskeneli H, Aydin SZ, Merkel PA. Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S86-S91.
49. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum. 2007;56(3):1000-1009.
50. Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine. 2015;94(14):e622.
51. Dagna L, Salvo F, Tiraboschi M, et al. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med. 2011;155(7):425-433.
52. Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis. Circulation. 2017;136(12):1114-1122.
53. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318-323.
54. de Souza AW, de Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis. J Autoimmun. 2014;48-49:79-83